|
(1 of 2) Florida Minority Cancer Research & Training Center: Feasibility Studies
|
5P20CA192990-04
|
$165,747
|
REAMS, ROMONIA
|
FLORIDA AGRICULTURAL AND MECHANICAL UNIV
|
|
(1) Intestinal Organoid Models for APC LOH
|
5R21CA208638-02
|
$192,406
|
GIARDINA, CHARLES
|
UNIVERSITY OF CONNECTICUT STORRS
|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
2U54CA163071-06
|
$1,427,230
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
3U54CA163071-07S1
|
$48,687
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
3U54CA163071-07S2
|
$85,299
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
3U54CA163071-07S3
|
$47,040
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
5U54CA163071-07
|
$1,619,382
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
(1/2) University of Guam/University of Hawaii Cancer Center Partnership
|
5U54CA143727-08
|
$1,188,362
|
PALAFOX, NEAL
|
UNIVERSITY OF HAWAII AT MANOA
|
|
(1/2) University of Guam/University of Hawaii Cancer Center Partnership
|
5U54CA143727-09
|
$1,119,110
|
PALAFOX, NEAL
|
UNIVERSITY OF HAWAII AT MANOA
|
|
(10.) The Gut Microbiome and Responses to Neoadjuvant Chemoradiation in Rectal Cancer Patients
|
5R21CA205636-02
|
$202,275
|
CHEN, GRACE
|
UNIVERSITY OF MICHIGAN
|
|
(2/2) CDU/UCLA Cancer Center Partnership to Eliminate Cancer Health Disparities
|
5U54CA143930-08
|
$704,474
|
FARIAS-EISNER, ROBIN
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
(2/2) CDU/UCLA Cancer Center Partnership to Eliminate Cancer Health Disparities
|
5U54CA143930-09
|
$714,423
|
FARIAS-EISNER, ROBIN
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
(2/2) TUFCCC/HC Regional Comprehensive Cancer Health Disparity Partnership
|
1U54CA221704-01A1
|
$1,050,067
|
OGUNWOBI, OLORUNSEUN
|
HUNTER COLLEGE
|
|
(6) Molecular mechanisms explaining premalignant changes in the etiology of melanoma
|
1R21CA208736-01A1
|
$146,000
|
MURPH, MANDI
|
UNIVERSITY OF GEORGIA
|
|
(7) Novel imaging devices for measurement and control of tumor microenvironments
|
1R01CA216248-01
|
$565,675
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
(8) Mechanisms of autoimmune endocrine diseases in patients receiving checkpoint inhibitors
|
1R01CA227473-01
|
$580,767
|
HEROLD, KEVAN
|
YALE UNIVERSITY
|
|
(8) Mechanisms of autoimmune endocrine diseases in patients receiving checkpoint inhibitors
|
3R01CA227473-01S1
|
$293,469
|
HEROLD, KEVAN
|
YALE UNIVERSITY
|
|
(ACCSIS) Accelerating Colorectal Cancer Screening through Implementation Science in Appalachia
|
1UG3CA233282-01
|
$770,562
|
DIGNAN, MARK
|
UNIVERSITY OF KENTUCKY
|
|
(NSF: 2018 GENERAL SOCIAL SURV) ADDING GLOBAL HEALTH ITEMS TO THE 2018 GENERAL SOCIAL SURVEY
|
APC17004
|
$187,328
|
UNKNOWN, UNKNOWN
|
NATIONAL SCIENCE FOUNDATION
|
|
(PQ #10) Gut-brain interactions underlying chemotherapy-induced behavioral comorbidities
|
1R01CA216290-01
|
$338,903
|
PYTER, LEAH
|
OHIO STATE UNIVERSITY
|
|
(PQ #10) Gut-brain interactions underlying chemotherapy-induced behavioral comorbidities
|
5R01CA216290-02
|
$309,819
|
PYTER, LEAH
|
OHIO STATE UNIVERSITY
|
|
(PQ #4) Single cell barcoding for studies of study clonal evolution in glioblastoma
|
5R01CA190121-05
|
$362,088
|
VERHAAK, ROELAND
|
JACKSON LABORATORY
|
|
(PQ 6) Exploiting Frequent Alterations in the PRC2 Complex to Distinguish Benign Neurofibromas from Malignant Peripheral Nerve Sheath Tumors
|
5R21CA208723-02
|
$177,852
|
BETTEGOWDA, CHETAN
|
JOHNS HOPKINS UNIVERSITY
|
|
(PQ 9) Dysregulation of epidermal MMP-13 as cause of paclitaxel-induced peripheral neuropathy
|
1R01CA215973-01
|
$443,022
|
RIEGER, SANDRA
|
MOUNT DESERT ISLAND BIOLOGICAL LAB
|
|
(PQ 9) Synaptic basis of deficits in attention and executive function following cranial radiation
|
5R01CA208535-02
|
$451,564
|
GROSSHANS, DAVID
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
(PQ 9) Synaptic basis of deficits in attention and executive function following cranial radiation
|
5R01CA208535-03
|
$506,533
|
GROSSHANS, DAVID
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
(PQ#9): Altered mitochondrial transport and chemotherapy-induced peripheral neuropathy
|
1R21CA215985-01
|
$198,000
|
CHANG, KAREN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
(PQ#9): Altered mitochondrial transport and chemotherapy-induced peripheral neuropathy
|
5R21CA215985-02
|
$165,000
|
CHANG, KAREN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.
|
3R01CA206025-03S1
|
$52,355
|
GUISE, THERESA
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.
|
5R01CA206025-02
|
$637,172
|
GUISE, THERESA
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.
|
5R01CA206025-03
|
$630,724
|
GUISE, THERESA
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
(PQ1) Adaptive immune and microbial mechanisms regulating Lynch syndrome penetrance
|
1R01CA231283-01
|
$501,220
|
LIPKIN, STEVEN
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
|
(PQ1) Cellular senescence as an initiating event in malignant transformation
|
1R21CA206013-01A1
|
$203,400
|
DAVID, GREGORY
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
(PQ1) Characterization of Premalignant Fields in a Murine Model of Head and Neck and Esophageal Cancers
|
5R01CA205258-02
|
$464,261
|
GUDAS, LORRAINE
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
|
(PQ1) Epigenetic effects of the premalignant field
|
5R01CA208620-02
|
$372,671
|
TERADA, LANCE
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
(PQ1) Epigenetic effects of the premalignant field
|
5R01CA208620-03
|
$415,599
|
TERADA, LANCE
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
(PQ1) GUCY2C hormone loss translates APC-Beta-catenin mutations into epithelial transformation
|
5R01CA206026-02
|
$356,850
|
WALDMAN, SCOTT
|
THOMAS JEFFERSON UNIVERSITY
|
|
(PQ1) GUCY2C hormone loss translates APC-Beta-catenin mutations into epithelial transformation
|
5R01CA206026-03
|
$356,850
|
WALDMAN, SCOTT
|
THOMAS JEFFERSON UNIVERSITY
|
|
(PQ1) Molecular circuit of multi-ciliogenesis regulates choroid plexus differentiation and tumor development
|
5R01CA220551-03
|
$315,193
|
ZHAO, HAOTIAN
|
NEW YORK INST OF TECHNOLOGY
|
|
(PQ1) Molecular circuit of multi-ciliogenesis regulates choroid plexus differentiation and tumor development
|
1R01CA220551-01
|
$383,749
|
ZHAO, HAOTIAN
|
SANFORD RESEARCH/USD
|
|
(PQ1) Progenitor cell malfunction, mutations and changes in microenvironment: A dynamic risk spectrum for cancer evolution
|
1R01CA219893-01
|
$442,614
|
GHOSH, MOUMITA
|
NATIONAL JEWISH HEALTH
|
|
(PQ1) Progenitor cell malfunction, mutations and changes in microenvironment: A dynamic risk spectrum for cancer evolution
|
5R01CA219893-02
|
$427,989
|
GHOSH, MOUMITA
|
NATIONAL JEWISH HEALTH
|
|
(PQ1) Progression of the airway field of injury to Kras mutant lung cancer
|
5R01CA205608-02
|
$346,909
|
SCHEET, PAUL
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
(PQ1) Progression of the airway field of injury to Kras mutant lung cancer
|
5R01CA205608-03
|
$346,909
|
SCHEET, PAUL
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
(PQ10) Do microbiota alter the epigenetic landscape in human genome
|
5R21CA208464-02
|
$212,063
|
STRONGIN, ALEX
|
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST
|
|
(PQ11) Dietary strategies to enhance FOLFOX cancer therapies
|
1R21CA231255-01
|
$189,744
|
ROSENBERG, DANIEL
|
UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
|
|
(PQ11) Reversing exosome-mediated immune suppression - a novel strategy for cancer therapy
|
5R21CA205644-02
|
$202,439
|
WHITESIDE, THERESA
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
(PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer.
|
5R01CA208644-02
|
$377,438
|
CRITTENDEN, MARKA
|
PROVIDENCE PORTLAND MEDICAL CENTER
|
|
(PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer.
|
5R01CA208644-03
|
$377,438
|
CRITTENDEN, MARKA
|
PROVIDENCE PORTLAND MEDICAL CENTER
|
|
(PQ12) Enhancement of DNA repair in neurons via a targeted APE1 small molecule modifier to decrease and reverse chemotherapy-induced peripheral neuropathy (CIPN)
|
1R01CA231267-01
|
$460,814
|
FEHRENBACHER, JILL
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|